-
1
-
-
0036362181
-
Why the epidermal growth factor receptor? The rationale for cancer therapy
-
Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 2002;7(Suppl 4):2-8.
-
(2002)
Oncologist.
, vol.7
, pp. 2-8
-
-
Baselga, J.1
-
2
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon D, Clark G, Wong S, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785): 177-182.
-
(1987)
Science.
, vol.235
, Issue.4785
, pp. 177-182
-
-
Slamon, D.1
Clark, G.2
Wong, S.3
-
3
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized Anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. J Clin Oncol. 1999;17(9):2639-2648.
-
(1999)
J Clin Oncol.
, vol.17
, Issue.9
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
-
4
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med. 2001; 344(11):783-792.
-
(2001)
N Engl J Med.
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
5
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med. 2005;353(16):1659-1672.
-
(2005)
N Engl J Med.
, vol.353
, Issue.16
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
-
6
-
-
84862914692
-
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
-
Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med. 2012;366(2):109-119.
-
(2012)
N Engl J Med.
, vol.366
, Issue.2
, pp. 109-119
-
-
Baselga, J.1
Cortés, J.2
Kim, S.-B.3
-
7
-
-
0041885349
-
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
-
Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm. J Clin Oncol. 2003;21(15):2889-2895.
-
(2003)
J Clin Oncol.
, vol.21
, Issue.15
, pp. 2889-2895
-
-
Burstein, H.J.1
Harris, L.N.2
Marcom, P.K.3
-
8
-
-
33344478381
-
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
-
Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer. N Engl J Med. 2006;354(8):809-820.
-
(2006)
N Engl J Med.
, vol.354
, Issue.8
, pp. 809-820
-
-
Joensuu, H.1
Kellokumpu-Lehtinen, P.-L.2
Bono, P.3
-
9
-
-
84879473563
-
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006
-
Rimawi MF, Mayer IA, Forero A, et al. Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006. J Clin Oncol. 2013;31(14):1726-1731.
-
(2013)
J Clin Oncol.
, vol.31
, Issue.14
, pp. 1726-1731
-
-
Rimawi, M.F.1
Mayer, I.A.2
Forero, A.3
-
10
-
-
84855297353
-
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial
-
Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
-
(2012)
Lancet Oncol.
, vol.13
, Issue.1
, pp. 25-32
-
-
Gianni, L.1
Pienkowski, T.2
Im, Y.-H.3
-
11
-
-
84879474424
-
Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: One more step toward chemotherapy-free therapy
-
Prat A, Baselga J. Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Hormonal Therapy for the Treatment of Primary HER2-Positive Breast Cancer: One More Step Toward Chemotherapy-Free Therapy. J Clin Oncol. 2013;31(14):1703-1706.
-
(2013)
J Clin Oncol.
, vol.31
, Issue.14
, pp. 1703-1706
-
-
Prat, A.1
Baselga, J.2
-
12
-
-
84877028141
-
Comprehensive molecular portraits of human breast tumours
-
TCGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
-
(2012)
Nature
, vol.490
, Issue.7418
, pp. 61-70
-
-
TCGA1
-
13
-
-
62449131093
-
Supervised risk predictor of breast cancer based on intrinsic subtypes
-
Parker JS, Mullins M, Cheang MCU, et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. J Clin Oncol. 2009;27(8):1160-1167.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.8
, pp. 1160-1167
-
-
Parker, J.S.1
Mullins, M.2
Cheang, M.C.U.3
-
14
-
-
78951482208
-
Deconstructing the molecular portraits of breast cancer
-
Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5-23.
-
(2011)
Mol Oncol.
, vol.5
, Issue.1
, pp. 5-23
-
-
Prat, A.1
Perou, C.M.2
-
15
-
-
51149092061
-
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2
-
Prat A, Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Prac Oncol. 2008;5(9):531-542.
-
(2008)
Nat Clin Prac Oncol.
, vol.5
, Issue.9
, pp. 531-542
-
-
Prat, A.1
Baselga, J.2
-
16
-
-
84887104840
-
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: New insights into molecular interactions and clinical implications
-
Montemurro F, Di Cosimo S, Arpino G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol. 2013;24(11):2715-2724.
-
(2013)
Ann Oncol.
, vol.24
, Issue.11
, pp. 2715-2724
-
-
Montemurro, F.1
Di Cosimo, S.2
Arpino, G.3
-
17
-
-
77957940993
-
High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer
-
Staaf J, Jonsson G, Ringner M, et al. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res. 2010;12(3):R25.
-
(2010)
Breast Cancer Res.
, vol.12
, Issue.3
, pp. R25
-
-
Staaf, J.1
Jonsson, G.2
Ringner, M.3
-
18
-
-
33847063053
-
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
-
Carey LA, Dees EC, Sawyer L, et al. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clin Cancer Res. 2007;13(8):2329-2334.
-
(2007)
Clin Cancer Res.
, vol.13
, Issue.8
, pp. 2329-2334
-
-
Carey, L.A.1
Dees, E.C.2
Sawyer, L.3
-
19
-
-
33744960226
-
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
-
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502.
-
(2006)
JAMA
, vol.295
, Issue.21
, pp. 2492-2502
-
-
Carey, L.A.1
Perou, C.M.2
Livasy, C.A.3
-
20
-
-
0034680102
-
Molecular portraits of human breast tumours
-
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
-
(2000)
Nature
, vol.406
, Issue.6797
, pp. 747-752
-
-
Perou, C.M.1
Sorlie, T.2
Eisen, M.B.3
-
21
-
-
84655169981
-
Practical implications of gene-expression-based assays for breast oncologists
-
Prat A, Ellis M, Perou C. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol. 2011;9(1):48-57
-
(2011)
Nat Rev Clin Oncol.
, vol.9
, Issue.1
, pp. 48-57
-
-
Prat, A.1
Ellis, M.2
Perou, C.3
-
22
-
-
0037478605
-
Repeated observation of breast tumor subtypes in independent gene expression data sets
-
Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418-8423.
-
(2003)
Proc Natl Acad Sci U S A.
, vol.100
, Issue.14
, pp. 8418-8423
-
-
Sorlie, T.1
Tibshirani, R.2
Parker, J.3
-
24
-
-
84872550777
-
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer
-
Prat A, Cheang MCU, Martín M, et al. Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer. J Clin Oncol. 2013;31(2):203-209.
-
(2013)
J Clin Oncol.
, vol.31
, Issue.2
, pp. 203-209
-
-
Prat, A.1
Cheang, M.C.U.2
Martín, M.3
-
25
-
-
78049453780
-
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer
-
Nielsen TO, Parker JS, Leung S, et al. A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2010;16(21):5222-5232.
-
(2010)
Clin Cancer Res.
, vol.16
, Issue.21
, pp. 5222-5232
-
-
Nielsen, T.O.1
Parker, J.S.2
Leung, S.3
-
26
-
-
84859839286
-
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial
-
Cheang MCU, Voduc KD, Tu D, et al. Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial. Clin Cancer Res. 2012;18(8):2402-2412.
-
(2012)
Clin Cancer Res.
, vol.18
, Issue.8
, pp. 2402-2412
-
-
Cheang, M.C.U.1
Voduc, K.D.2
Tu, D.3
-
27
-
-
84865100704
-
A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
-
Chia SK, Bramwell VH, Tu D, et al. A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen. Clin Cancer Res. 2012;18(16):4465-4472.
-
(2012)
Clin Cancer Res.
, vol.18
, Issue.16
, pp. 4465-4472
-
-
Chia, S.K.1
Bramwell, V.H.2
Tu, D.3
-
28
-
-
84865191389
-
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
-
Esserman L, Berry D, Cheang M, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012;132(3): 1049-1062.
-
(2012)
Breast Cancer Res Treat.
, vol.132
, Issue.3
, pp. 1049-1062
-
-
Esserman, L.1
Berry, D.2
Cheang, M.3
-
29
-
-
79959268722
-
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031
-
Ellis MJ, Suman VJ, Hoog J, et al. Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype - ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342-2349.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.17
, pp. 2342-2349
-
-
Ellis, M.J.1
Suman, V.J.2
Hoog, J.3
-
30
-
-
84884762173
-
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy
-
Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy. J Clin Oncol. 2013;31(22):2783-2790.
-
(2013)
J Clin Oncol.
, vol.31
, Issue.22
, pp. 2783-2790
-
-
Dowsett, M.1
Sestak, I.2
Lopez-Knowles, E.3
-
31
-
-
84861527388
-
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
-
Curtis C, Shah SP, Chin S-F, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346-352.
-
(2012)
Nature
, vol.486
, Issue.7403
, pp. 346-352
-
-
Curtis, C.1
Shah, S.P.2
Chin, S.-F.3
-
32
-
-
84883325272
-
Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
-
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206-2223.
-
(2013)
Ann Oncol.
, vol.24
, Issue.9
, pp. 2206-2223
-
-
Goldhirsch, A.1
Winer, E.P.2
Coates, A.S.3
-
33
-
-
33847147313
-
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
-
Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol. 2007;25(1):118-145.
-
(2007)
J Clin Oncol.
, vol.25
, Issue.1
, pp. 118-145
-
-
Wolff, A.C.1
Hammond, M.E.H.2
Schwartz, J.N.3
-
34
-
-
0035942271
-
Significance analysis of microarrays applied to the ionizing radiation response
-
Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98(9):5116-5121.
-
(2001)
Proc Natl Acad Sci USA.
, vol.98
, Issue.9
, pp. 5116-5121
-
-
Tusher, V.G.1
Tibshirani, R.2
Chu, G.3
-
35
-
-
67649472398
-
Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3
-
Baselga J, Swain S. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463-475.
-
(2009)
Nat Rev Cancer.
, vol.9
, Issue.7
, pp. 463-475
-
-
Baselga, J.1
Swain, S.2
-
37
-
-
0037099532
-
Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and Akt is Required for Antibodymediated Effects on p27, Cyclin D1, and Antitumor Action
-
Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and Akt Is Required for Antibodymediated Effects on p27, Cyclin D1, and Antitumor Action. Cancer Res. 2002;62(14):4132-4141.
-
(2002)
Cancer Res.
, vol.62
, Issue.14
, pp. 4132-4141
-
-
Yakes, F.M.1
Chinratanalab, W.2
Ritter, C.A.3
-
38
-
-
80052728749
-
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data from NCCTG N9831 and NSABP B-31
-
Perez EA, Romond EH, Suman VJ, et al. Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366-3373.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.25
, pp. 3366-3373
-
-
Perez, E.A.1
Romond, E.H.2
Suman, V.J.3
-
39
-
-
84866784769
-
Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: A prospective cohort study
-
Vaz-Luis I, Ottesen R, Hughes M, et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012;14(5):R129.
-
(2012)
Breast Cancer Res.
, vol.14
, Issue.5
, pp. R129
-
-
Vaz-Luis, I.1
Ottesen, R.2
Hughes, M.3
-
40
-
-
75149145066
-
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort
-
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377-384.
-
(2010)
Lancet.
, vol.375
, Issue.9712
, pp. 377-384
-
-
Gianni, L.1
Eiermann, W.2
Semiglazov, V.3
-
41
-
-
84864018421
-
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
-
Guarneri V, Frassoldati A, Bottini A, et al. Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study. J Clin Oncol. 2012;30(16):1989-1995.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.16
, pp. 1989-1995
-
-
Guarneri, V.1
Frassoldati, A.2
Bottini, A.3
-
42
-
-
84857236823
-
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, openlabel, multicentre, phase 3 trial
-
Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, openlabel, multicentre, phase 3 trial. Lancet. 2012;379(9816):633-640.
-
(2012)
Lancet.
, vol.379
, Issue.9816
, pp. 633-640
-
-
Baselga, J.1
Bradbury, I.2
Eidtmann, H.3
-
43
-
-
84856444501
-
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): A randomised phase 3 trial
-
Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135-144.
-
(2012)
Lancet Oncol.
, vol.13
, Issue.2
, pp. 135-144
-
-
Untch, M.1
Loibl, S.2
Bischoff, J.3
-
44
-
-
84885416696
-
Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer
-
Carey L, Berry D, Ollila D, et al. Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. Proc Am Soc Clin Oncol: a500. 2013.
-
(2013)
Proc Am Soc Clin Oncol: A500
-
-
Carey, L.1
Berry, D.2
Ollila, D.3
-
45
-
-
84892776195
-
The research-based PAM50 subtype predictor identifies higher pathological responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study
-
Prat A, Bianchini G, Pickl M, et al. The research-based PAM50 subtype predictor identifies higher pathological responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res. 2014;20(2):511-521.
-
(2014)
Clin Cancer Res.
, vol.20
, Issue.2
, pp. 511-521
-
-
Prat, A.1
Bianchini, G.2
Pickl, M.3
|